GrandRoundsCLL15TARGET AUDIENCE OVERVIEW OF ACTIVITY This is a watershed moment in the management of CLL, but with the many exciting advances that are rapidly occurring, a number of vexing questions and clinical challenges are simultaneously emerging as well. To bridge the gap between research and patient care, this video presentation by Dr John P Leonard uses a review of recent relevant publications and presentations, ongoing clinical trials and clinical investigator treatment preferences to assist medical oncologists, hematologists and other healthcare providers involved in the treatment of CLL with the formulation of up-to-date clinical management strategies. LEARNING OBJECTIVES
ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Presenting Faculty Member John P Leonard, MD Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Spectrum Pharmaceuticals Inc. Project Steering Committee Members Jennifer R Brown, MD, PhD Advisory Committee: Celgene Corporation, Emergent BioSolutions Inc, Gilead Sciences Inc, Janssen Biotech Inc, MorphoSys, Pharmacyclics Inc, ProNAi Therapeutics Inc; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Emergent BioSolutions Inc, Genentech BioOncology, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, MorphoSys, Pharmacyclics Inc, ProNAi Therapeutics Inc, Roche Laboratories Inc. Andrew M Evens, DO Advisory Committee and Consulting Agreements: Celgene Corporation, Genentech BioOncology, Takeda Oncology; Contracted Research: Takeda Oncology; Speakers Bureau: Celgene Corporation. Ian W Flinn, MD, PhD Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Takeda Oncology. Jeff Sharman, MD Advisory Committee: Celgene Corporation, Gilead Sciences Inc, Pharmacyclics Inc; Consulting Agreement: Celgene Corporation; Contracted Research: Celgene Corporation, Cephalon Inc, Genentech BioOncology, Gilead Sciences Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics Inc, Takeda Oncology. Mitchell R Smith, MD, PhD Consulting Agreements: Celgene Corporation, Spectrum Pharmaceuticals Inc, Takeda Oncology; Contracted Research: Abbott Laboratories. Sonali M Smith, MD Consulting Agreements: Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, ImmunogeniX Research LLC, Pharmacyclics Inc, TG Therapeutics Inc; Data and Safety Monitoring Board: Genentech BioOncology. Michael E Williams, MD, ScM Advisory Committee: Celgene Corporation, Takeda Oncology, TG Therapeutics Inc; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Takeda Oncology, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Janssen Biotech Inc, Pharmacyclics Inc, Novartis Pharmaceuticals Corporation, Takeda Oncology. PROJECT CHAIR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from AbbVie Inc, Genentech BioOncology, Gilead Sciences Inc and Pharmacyclics Inc. Hardware/Software Requirements: Last review date: November 2015 |